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Purpose: To develop a nomogram predictive of current bone scan positivity in patients
receiving androgen-deprivation therapy (ADT) for advanced prostate cancer; to augment
clinical judgment and highlight patients in need of additional imaging investigations.
Materials and methods: A retrospective chart review of bone scan records (conventional
99mTc-scintigraphy) of 1,293 patients who received ADT at the Memorial Sloan-Kettering
Cancer Center from 2000 to 2011. Multivariable logistic regression analysis was used to
identify variables suitable for inclusion in the nomogram. The probability of current bone
scan positivity was determined using these variables and the predictive accuracy of the
nomogram was quantified by concordance index.
Results: In total, 2,681 bone scan records were analyzed and 636 patients had a positive
result. Overall, the median pre-scan prostate-specific antigen (PSA) level was 2.4 ng/ml;
median PSA doubling time (PSADT) was 5.8 months. At the time of a positive scan,
median PSA level was 8.2 ng/ml; 53% of patients had PSA <10 ng/ml; median PSADT
was 4.0 months. Five variables were included in the nomogram: number of previous neg-
ative bone scans after initiating ADT, PSA level, Gleason grade sum, and history of radical
prostatectomy and radiotherapy. A concordance index value of 0.721 was calculated for
the nomogram. This was a retrospective study based on limited data in patients treated in
a large cancer center who underwent conventional 99mTc bone scans, which themselves
have inherent limitations.
Conclusion: This is the first nomogram to predict current bone scan positivity in
ADT-treated prostate cancer patients, providing high predictive accuracy.
Keywords: non-steroidal anti-androgens, radionuclide imaging, nomogram, prostatic neoplasms, androgen-
deprivation therapy, bone scan positivity
INTRODUCTION
Between 15 and 40% of patients treated for localized prostate
cancer will experience biochemical recurrence (BCR), as shown
by rising prostate-specific antigen (PSA) levels (1). Androgen-
deprivation therapy (ADT) is an accepted standard of care for
patients who have received therapy with curative intent and sub-
sequently show systemic relapse (2). Castration-resistant prostate
cancer (CRPC) is defined as disease progression, typically iden-
tified by rising PSA levels and/or worsening disease according to
imaging, despite castration levels of testosterone; most patients
with CRPC will eventually develop metastatic (M1) disease (3).
The axial skeleton is the most common site of systemic metasta-
sis in patients with prostate cancer (4). Recent prospective studies
Abbreviations: ADT, androgen-deprivation therapy; BCR, biochemical recurrence;
CRPC, castration-resistant prostate cancer; M0, non-metastatic; M1, metastatic;
PET, positron emission tomography; PSA, prostate-specific antigen; PSADT, PSA
doubling time.
demonstrated a median time of approximately 25–30 months
from CRPC to M1 CRPC (3, 5, 6). M1 bone disease is associ-
ated with significant morbidity, including pain, impaired mobility,
and pathological fractures (7). Bone imaging can provide impor-
tant information on the clinical status of asymptomatic patients
with rising PSA levels. In addition, novel therapies, some of which
provide benefits for patients with asymptomatic M1 CRPC, have
recently been developed and approved (8, 9).
Although higher PSA levels and more rapid PSA doubling times
(PSADT) are associated with a shorter time to bone metastasis
(5, 10), the National Comprehensive Cancer Network prostate
cancer guidelines provide minimal guidance on when to start
and how often to repeat bone scan imaging in BCR patients
(11). A recent study suggests that many patients classified as
having non-metastatic (M0) disease are not undergoing early
imaging and detection of the transition to the M1 state. In
the ENTHUSE trial, a phase III trial enrolling men with M0
CRPC, 32% of screened men actually had M1 disease (based on
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magnetic resonance imaging, computed tomography, or bone scan
results) (12).
Nomograms can provide individualized, disease-specific risk
estimations that aid clinical management decisions (13). However,
no nomogram is currently available to predict bone scan positivity
in patients receiving ADT, information that could prompt rele-
vant imaging investigations. We therefore investigated disease and
treatment-related factors that could be predictive of metastases in
this patient population, and used these factors to develop a nomo-
gram model. To achieve this, we reviewed the records of a large
database of patients treated at a single institution over an 11-year
period who underwent conventional 99mTc-scintigraphy.
MATERIALS AND METHODS
This retrospective chart review included patients treated at the
Memorial Sloan-Kettering Cancer Center for prostate adenocar-
cinoma from 2000 to 2011. All patients with bone scan records
who had received ADT during this period were included in the
study, with the exception of patients participating in clinical tri-
als and those who had received prior chemotherapy or estrogen
therapy (which could affect the time to bone scan positivity).
Data on the frequencies of visits and reasons for the bone scans
being performed were not collected. Patients were followed up
from the initiation of ADT until either the first positive bone
scan or the last hospital visit. Patients may have received either
intermittent or continuous ADT, but these data were not col-
lected. Data on the use of calcium, vitamin D, or bisphosphonates
were not collected as these were not expected to affect bone scan
positivity.
A chart review of patients’ records was undertaken. A scan
was coded “positive” if terms referring to metastases were iden-
tified in the records, “negative” if no such terms were found, and
“unknown” if records had equivocal findings. Based on clinical
relevance and data availability, eight disease and treatment vari-
ables were evaluated as potential predictors of a positive 99mTc
bone scan: number of previous negative bone scans; current
PSA level; PSADT; most recent Gleason grade sum (at most
recent biopsy or at prostatectomy); and a history of prior rad-
ical prostatectomy, radiotherapy, brachytherapy, or cryotherapy.
PSADT was calculated based on all PSA data points measured
prior to each bone scan and the interval(s) between them; negative
PSADT indicated a decrease in PSA level from the previous read-
ing. The radiotherapy group included all patients who received
treatment related to the prostate. Missing values were multiply
imputed before conducting statistical analyses. Testosterone data
were not available for all patients and were not included in the
analysis.
Multivariable logistic regression analysis was used to deter-
mine which factors should be included in the nomogram model.
Restricted cubic splines were applied to continuous or nominal
variables with the purpose of relaxing the commonly assumed lin-
ear association between risk factors and the outcome. Variables
were selected using the step-down model reduction method (14)
and identified predictors were included in the final parsimonious
model on which the nomogram was built. Generalized estimat-
ing equations were used to handle clustering bone scans from the
same patient. The current probability of a positive bone scan was
determined by the nomogram using the patient variables at the
time of each bone scan, and the predictive accuracy of the model
was quantified using Harrell’s concordance index (C-index) (15).
The C-index is equivalent to the area under the receiver operating
characteristic curve and values can range from 0.5, which indi-
cates no predictive discrimination, to 1.0, which denotes a perfect
separation of patients with different outcomes (16, 17). Bootstrap-
ping with 1,000 resamples was utilized to correct over-fitting bias
for both the model discrimination and calibration evaluations.
All statistical analyses and graphics were conducted using the
open-source statistical software R version 2.14.2 (R Foundation for
Statistical Computing, Vienna, Austria) in combination with the
additional packages Design (Frank Harrell, Vanderbilt University,
Nashville, TN, USA) and Zelig (Harvard University, Cambridge,
MA, USA). The statistical hypothesis test was considered to be
significant if p< 0.05.
RESULTS
A total of 1,293 patients received ADT at the Memorial Sloan-
Kettering Cancer Center between 2000 and 2011 and underwent
at least one 99mTc bone scan during the median follow-up period
of 54 months (range 3.4–144 months) from ADT initiation; 869
patients had at least one scan during ADT. Of the 424 patients who
had either no scan during ADT or an unknown ADT end date, 298
had a post-ADT scan with a known ADT end date. Overall, 2,681
bone scan records were analyzed and the disease characteristics at
the time of each bone scan are shown in Table 1.
Of the 1,293 patients included in the study, 636 had a positive
bone scan (Table 2). A median of 0 (range 0–15) negative scans
were conducted after the initiation of ADT but prior to obtaining a
positive scan, and the median time between the last negative scan
and the positive scan was 6.7 months (range 0.5–46.7 months).
Median PSA level prior to each positive bone scan was 8.2 ng/ml
(range 0–4,648 ng/ml) and median PSADT was 4.0 months (range
-120 to 120 months). Around half (53%) of the patients had PSA
levels <10 ng/ml at the time of their first positive scan.
Multivariable logistic regression analysis revealed that five vari-
ables were significant predictors of having a positive bone scan:
low number of previous negative bone scans after initiating ADT,
high PSA levels, high Gleason grade sum, and having no history of
radical prostatectomy or radiotherapy (Table 3). These variables
were then incorporated into the nomogram model. Brachyther-
apy, cryotherapy, and PSADT were not predictive of a positive scan
(data not shown) and were not included. The final nomogram
model is shown in Figure 1.
A C-index value of 0.721 was calculated for the nomogram
model. As shown in Figure 2, a close relationship was observed
between the results achieved with the nomogram model and the
actual clinical findings (ideal calibration result).
DISCUSSION
The nomogram model presented in this study is the first analytical
tool developed to predict current bone scan positivity in prostate
cancer patients treated with ADT. A C-index value of 0.721 was
calculated for the nomogram model, indicating high predictive
accuracy. This simple nomogram could therefore be used to high-
light patients in the clinic who should be a high priority for bone
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Table 1 | Patient and disease characteristics at each bone scan
(n=2,681).
Median (range) PSA level prior to each bone scan, ng/ml 2.4 (0–4,648)
Median (range) PSADT prior to each bone scan, monthsa 5.8 (−120–120)
Scan result, n (%)
Positive 636 (23.7)
Negative 2,045 (76.3)
Most recent Gleason grade sum, n (%)
≤6 267 (10.0)
7 944 (35.2)
8 606 (22.6)
9 787 (29.4)
10 63 (2.3)
Missing 14 (0.5)
Pre-scan radiotherapy, n (%)b
Yes 1,390 (51.8)
No 1,291 (48.2)
Pre-scan radical prostatectomy, n (%)
Yes 872 (32.5)
No 1,809 (67.5)
Pre-scan brachytherapy, n (%)
Yes 202 (7.5)
No 2,479 (92.5)
Pre-scan cryotherapy, n (%)
Yes 25 (0.9)
No 2,656 (99.1)
aPSADT was calculated based on the PSA levels measured prior to each bone
scan; negative PSADT values indicated a decrease in PSA levels from the previ-
ous reading. Median (range) number of PSA values used was 13 (2–99); 95.3%
of PSADT was calculated using 3 or more PSA values.
bThe radiotherapy group included all patients who received treatment related to
the prostate.
scan. This could offer substantial benefits to patients, as earlier
detection of the transition from M0 to M1 CRPC may allow earlier
therapeutic intervention.
Current National Comprehensive Cancer Network guide-
lines state that a bone scan is appropriate in men with post-
prostatectomy BCR (i.e., patients who have not received ADT)
when symptoms develop or PSA levels increase rapidly (11). How-
ever, to date, there has not been sufficient clinical evidence to
provide recommendations on imaging in men treated with ADT
and, at present, the transition of patients from M0 to M1 CRPC
is frequently missed (12). In the absence of detailed guidance on
when to initiate imaging in ADT-treated patients with prostate
cancer, our nomogram therefore has important clinical applica-
tions. For example, it could reduce potential physician subjectivity,
and highlight patients who should receive an additional bone scan.
Indeed, there is evidence across various therapeutic areas that
nomograms can be an effective tool in predicting clinical out-
comes in individual patients (18–21), with one nomogram model
predicting future bone scan positivity in prostate cancer patients
who had not received ADT more accurately than a group of expert
clinicians (C-index values 0.812 vs. 0.628) (22). There is therefore a
Table 2 | Patient and disease characteristics at the time of the first
positive scan (n=636).
Median (range) PSA level prior to each bone
scan, ng/ml
8.2 (0–4,648)
PSA level (ng/ml) category, n (%)
<5 271 (42.6)
5–10 68 (10.7)
10–20 57 (9.0)
20–50 82 (12.9)
50–100 52 (8.2)
≥100 106 (16.7)
Median (range) PSADT prior to each bone scan,
months
4.0 (−120–120)
Median (range) number of prior negative scans
after initiating ADT
0 (0–15)
Median (range) time since last negative bone
scan, months
6.7 (0.5–46.7)
Pre-scan radiotherapy, n (%)
Yes 242 (38.1)
No 394 (61.9)
Pre-scan radical prostatectomy, n (%)
Yes 147 (23.1)
No 489 (76.9)
Table 3 | Multivariable logistic regression analysis of the variables
included in the nomogram model.
Variable Comparison Odds ratioa (95% CI) p-value
PSA level (ng/ml) 13.7 vs. 0.2a 2.47 (2.07–2.93) <0.01
Number of previous
negative bone scans
after initiating ADT
2 vs. 0a 0.41 (0.33–0.51) <0.01
Most recent Gleason
grade sum
9 vs. 7a 1.58 (1.29–1.93) <0.01
Pre-scan radical
prostatectomy
Yes vs. No 0.63 (0.52–0.78) 0.01
Pre-scan radiotherapy Yes vs. No 0.76 (0.60–0.97) 0.03
aFor continuous variables, the third quartile (Q3) and first quartile (Q1) are shown
and were compared.
strong argument to use nomograms to augment clinical judgment
and prompt further imaging investigations.
During development of the nomogram, five factors were iden-
tified as predictive of current bone scan positivity: lower number
of previous negative bone scans after initiating ADT, higher PSA
level, higher Gleason grade sum, and having no history of radical
prostatectomy or radiotherapy. This is generally in line with pre-
vious findings in prostate cancer. Higher PSA levels (>10 ng/ml)
have been associated with a shorter time to first bone metasta-
sis in CRPC (5, 10), as well as decreased overall survival (10).
Several studies have also demonstrated the association between
higher Gleason scores and an increased risk of bone metastases
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FIGURE 1 | Nomogram model developed to predict current bone
scan positivity in patients treated with ADT for prostate cancer. The
result for each variable has a corresponding points score (top scale). The
points score for each variable is determined and summed to calculate
the total points for a given patient. This value is located on the total
points scale (second from the bottom). The predicted probability of
having a current positive bone scan is determined by drawing a vertical
line down from the total points scale to the probability scale below.
Number of previous negative bone scans should only include those after
the initiation of ADT.
in patients with newly diagnosed prostate cancer (23–25). Fur-
thermore, Gleason score and current PSA levels were significant
predictors of systemic progression in patients who had received
previous ADT or radiotherapy (26). Although these factors do
yield useful prognostic information, there is a clear need for new
predictors to be identified in future studies.
Data suggest that patients who have received ADT may have
a different risk of bone metastasis than those who have not, and
this should be taken into account when monitoring PSA levels.
In our study, PSA level at the time of a positive scan appeared
to be highly variable (range 0–4,648 ng/ml); however, the pro-
portion of patients with PSA levels <10 ng/ml at the time of
positive bone scan was high at 53%. A similar analysis in men
who had not received ADT found that PSA levels were lower at
the time of M1 diagnosis (25.9% of patients had PSA <10 ng/ml,
50.8% had PSA 10–100 ng/ml, and 23.3% had PSA >100 ng/ml)
(27). In another study, men with BCR on ADT were signifi-
cantly more likely to have a positive scan than patients who
had not received ADT, when the results were adjusted for PSA
level, PSADT, and PSA velocity (odds ratio 5.00; p= 0.004) (28).
These findings suggest that data obtained in patients who have
not received ADT cannot necessarily be extrapolated to patients
treated with ADT, and that rising PSA, irrespective of the absolute
value, should highlight the possibility of bone metastasis in this
patient population.
Although the simple nomogram that we have developed could
yield useful additional information to clinicians, we recognize that
our study has certain limitations. Firstly, the study population was
restricted to patients who underwent conventional 99mTc bone
scans, which themselves have inherent limitations. These have rel-
atively low specificity and sensitivity for detecting bone metastases
compared with other imaging techniques (29), and they are rarely
able to detect soft tissue or visceral metastases. Resources did
not allow us to confirm that all patients lacked a positive prior
bone scan. All patients with known prior positive bone scans were
excluded, and as such, this tool should not be used in a patient
who has a known prior positive bone scan. Secondly, this was
a retrospective study based on the limited data collected non-
systematically by different clinicians within a large cancer center.
For example, complete data on the timing of the development of
CRPC and bone metastases were not available, which could have
provided useful diagnostic information. External validation of the
nomogram is needed, and a prospective analysis with a clearly
defined testing and treatment algorithm would yield additional
valuable data to confirm and extend these findings. Thirdly, the
patients in this study were referred for treatment at the Memorial
Sloan-Kettering Cancer Center and may not be reflective of the
types of patients managed in the community setting. In addition,
the bone scan images were not obtained according to a specific
schedule, and the timing of bone scan imaging may have been
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FIGURE 2 | Calibration plot for the nomogram model showing
predicted vs. actual likelihood of having a positive bone scan is shown.
The vertical lines along the top of the figure show the distribution of
nomogram-predicted probabilities for patients in the study cohort.
influenced by disease or treatment factors that were not evaluated
in our chart review.
Avenues of further research became apparent during the course
of this analysis. The use of 99mTc bone scintigraphy as the stan-
dard first-line imaging technique is now being challenged by more
sensitive and more specific modalities, such as magnetic resonance
imaging and [18F]-fluoride positron emission tomography (PET)
(30). Evaluation of other imaging techniques used to detect bone
metastases in prostate cancer are already underway, most recently
the use of [18F] sodium fluoride PET as part of the National Onco-
logic PET Registry. The evidence gathered from this registry will
provide information on the clinical impact of sodium fluoride PET
in practice and the viability of expanding reimbursement to cover
sodium fluoride imaging. Therefore, nomograms that predict the
risk of metastases following the use of newer as well as existing
imaging techniques could also be developed. Secondly, the dis-
criminatory power of our nomogram, as indicated by the C-index,
was 0.721. Although this is comparatively high accuracy, there are
clearly additional factors that contribute to the development of the
M1 state. It is therefore important to identify these factors and to
understand their interaction with the predictors identified in this
analysis. Given that there are now several therapies developed for
the treatment of M1 CRPC, including sipuleucel-T, abiraterone
acetate, enzalutamide, and cabazitaxel, earlier detection may pro-
vide additional benefit for the patient. Finally, although our study
did not define the transition to CRPC, patients who developed
new bony metastases following the initiation of ADT have pre-
sumably already developed castration-resistant disease. Therefore,
the disease variables identified as accurate predictors of a posi-
tive bone scan in this study may also be predictive of the transition
from castration-sensitive disease to CRPC, which warrants further
investigation.
CONCLUSION
In conclusion, this study describes the first nomogram model to
predict current bone scan positivity with a high level of accu-
racy in patients with prostate cancer who have received ADT. The
nomogram could be used to highlight patients in the clinic who
should be a high priority for bone scan. Therefore, integrating this
nomogram into the clinical decision-making process could inform
decisions on imaging and allow earlier detection of metastases,
which could improve the care of ADT-treated patients.
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